ag-127 ag 127

AG 127 is a biochemical.

Tyrphostin AG 538 is a chalcone compound, an IGF-1 receptor kinase inhibitor (IC₅0 : for 400 nM) that is potent, cell-permeable, reversible, and competitive.

AG-270 is an allosteric and orally active inhibitor of MAT2A.

I-OMe-Tyrphostin AG 538 is a specific IGF-1R inhibitor and ATP-competitive inhibitor of PI5P4Kα (IC50: 1 µM).I-OMe-Tyrphostin AG 538 inhibits IGF-1R-mediated signaling and exhibits preferential cytotoxicity to nutrient-deficient PANC1 cells.

BAD (103-127) (human) acetate is a 25-mer Bad polypeptide from the BAD BH3 domain that antagonizes the effects of Bcl-xl.

AG-10 (Acoramidis) is an orally active and selective kinetic stabilizer of TTR (transthyretin). AG-10 exhibits activity for WT and V122I-TTR. AG-10 is used in the study of transthyretin amyloidosis.

AG-1557 hydrochloride is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase (pIC50: 8.194).

SV40 T-Ag-derived NLS peptide acetate (SV40 T-Ag-derived NLS peptide acetate) is a nuclear localization signal peptide. The DNA labeled with this peptide can be effectively transferred to the nucleus.

AG 045572 is a potent GnRH receptor antagonist that inhibits the GnRH receptor in humans and rats with Ki values of 6.0 nM and 3.8 nM, respectively.AG 045572 is metabolized by CYP3A and inhibits testosterone.

AG-1478 (NSC-693255) (Tyrphostin AG-1478) is a selective EGFR inhibitor.

AG-636 is a potent, reversible, and selective DHODH inhibitor with an IC50 of 17 nM and is orally active. It demonstrates strong anticancer effects.

Tyrphostin AG 528 (Tyrphostin B66) is an inhibitor of EGFR (IC50: 4.9 μM) and ErbB2 (IC50: 2.1 μM).

AG 555 (Tyrphostin B46) is an EGFR tyrosine kinase inhibitor.

AG-494 (Tyrphostin B48) is an inhibitor of epidermal growth factor receptor kinase.

AG 556 is a selective inhibitor of EGFR and blocks LPS-induced TNF-α production.

JH-II-127 is an oral inhibitor of leucine-rich repeat kinase 2 (LRRK2), targeting WT LRRK2, G2019S LRRK2, and A2016T LRRK2 with IC50 values of 6.6 nM, 2.2 nM, and 47.7 nM, respectively.

MSX-127 elicites positive response in peptide CXCR4.

AG1478 HCl is an epidermal growth factor receptor protein inhibitor.

AG-12286 is a pan-CDK inhibitor. AG-012986 may be useful in the treatment of tumors by inhibiting p38 MAPK phosphorylation. Note: many vendors confused the structure of AG-12286 (CAT#573461, CAS# 223784-75-6) with AG-012986 (CAT#406184, CAS# is 486414-35-1).

AG-024104 is a broad spectrum cyclin-dependent kinase inhibitors with potential anticancer activity.

AG-012917 is a broad spectrum cyclin-dependent kinase inhibitors with potential anticancer activity.

BAD (103-127) (human) is a 25-mer peptide obtained from the BH3 domain of BAD. It effectively counteracts the activity of Bcl-xL. Notably, BAD (103-127) (human) exhibits an approximately 800-fold greater binding affinity for Bcl-xL compared to the 16-mer peptide.

ABT-1812 is a bio-active chemical.

(rac)-AG-205 serves as a robust inhibitor of the progesterone receptor membrane component 1 (Pgrmc1), crucial for inducing genes linked to sterol synthesis, notably the INSIG1 protein, which interacts with PGRMC1. Additionally, it plays a pivotal role in mitigating neuronal resistance to hypoxic ischaemia by inhibiting NF-kB signalling and the activation of the BDNF/PI3K/AKT pathway.

AG 307 is a biochemical.

AG 84-10 is similar to Angiotensinogen 6-13. It is a peptidic substrate analog. It also has antihypertensive effects.

This peptide, a nuclear localization signal DNA tagged to this peptide efficiently translocates into the cell nucleus.

AG 1406 is a selective inhibitor of the receptor tyrosine kinase VEGF receptor 2.

AG 1295, a selective inhibitor of platelet-derived growth factor receptor (PDGFR) tyrosine-kinase, effectively halts PDGFR autophosphorylation without impacting the autophosphorylation of the EGF receptor[1][2][3][4].

AG-13958 monohydrochloride is the HCl salt of AG-13958 --- a VEGFA inhibitor potentially for the treatment of age-related macular degeneration. Neovascular AMD, a subtype characterized by the growth of new, pathologic blood vessels, results in most of the cases of severe and rapid vision loss associated with AMD. A critical activator of angiogenesis in neovascular AMD is VEGF.

AG-012986 is a multitargeted cyclin-dependent kinase (CDK) inhibitor active against CDK1, CDK2, CDK4/6, CDK5, and CDK9, with selectivity over a diverse panel of non-CDK kinases. AG-012986 showed antiproliferative activities in vitro with IC(50)s of <100 nmol/L in 14 of 18 tumor cell lines. In vivo, significant antitumor efficacy induced by AG-012986 was seen (tumor growth inhibition, >83.1%) in 10 of 11 human xenograft tumor models. AG-012986 also showed dose-dependent retinoblastoma Ser(795) hypophosphorylation, cell cycle arrest, decreased Ki-67 tumor staining, and apoptosis in conjunction with antitumor activity.

AG-012986 HCl is a multitargeted cyclin-dependent kinase (CDK) inhibitor active against CDK1, CDK2, CDK4/6, CDK5, and CDK9, with selectivity over a diverse panel of non-CDK kinases. AG-012986 HCl showed antiproliferative activities in vitro with IC(50)s of <100 nmol/L in 14 of 18 tumor cell lines. In vivo, significant antitumor efficacy induced by AG-012986 HCl was seen (tumor growth inhibition, >83.1%) in 10 of 11 human xenograft tumor models. AG-012986 HCl also showed dose-dependent retinoblastoma Ser(795) hypophosphorylation, cell cycle arrest, decreased Ki-67 tumor staining, and apoptosis in conjunction with antitumor activity.

Tyrphostin AG 568 promotes Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity. It also induces K562 to differentiate.

AG 85 is a major secretion protein of Mycobacterium tuberculosis.

CHMFL-PI4K-127 (compound 15g) is a highly selective inhibitor of PfPI4K (Plasmodium falciparum PI4K kinase) with oral activity (IC50=0.9 nM) and exhibits strong inhibitory activity against Plasmodium falciparum 3D7 (EC50=25.1 nM), demonstrating significant anti-malaria effects.

AG-024322 is a potent ATP-competitive inhibitor targeting pan-CDK, effectively inhibiting cell cycle kinases CDK1, CDK2, and CDK4 with Ki values in the 1-3 nM range (1-3 nM).

AG-120 (racemic), the racemic mixture of AG-120, is an orally available isocitrate dehydrogenase type 1 (IDH1) inhibitor, and shows potential antineoplastic activity.

AG-09/1 is a selective and potent formyl peptide receptor 1 (FPR1) agonist that activates chemotaxis in human neutrophils.

AG 370, an indole tyrphostin, is a potent inhibitor of PDGF-induced mitogenesis with an IC50 of 20 μM, and it shows weak inhibition of the EGF receptor.

AG 85-12 is a mimic of the C-terminal portion of angiotensin I.

AG 2000 is a biochemical.

Tyrphostin AG 112 is an inhibitor of EGFR phosphorylation.

AG-7404 is a potent protease inhibitor with anti-poliovirus activity. AG-7404 was active against all virus with EC50 values ranging from 0.080 to 0.674 μM. AG-7404 was fully active against V-073-resistant variants with EC50 values ranging from 0.218 to 0.

Tyrphostin AG 1112 is a Bcr-Abl kinase blocker. It can activate the terminal differentiation of K562 cells and the purging of Ph+ cells.

AG-1859, an HIV protease inhibitor, is used potentially for the treatment of HIV infection.

AG-825（Tyrphostin C15） is a selective and competitive ErbB2 inhibitor that inhibits tyrosine phosphorylation with an IC50 value of 0.35 μM.AG-825 (Tyrphostin C15) inhibits HER2 and shows anticancer activity in a mouse xenograft model of breast cancer.AG-825 ( Tyrphostin C15) is a potentially active molecule for overcoming manganese-induced neurotoxicity or the development of Alzheimer's disease, and promotes apoptosis in human neutrophils, which could be used in the study of breast cancer.

(E)-AG 99 ((E)-Tyrphostin AG 99) is an EGFR kinase inhibitor with an IC50 of 10 μM in the human epidermoid carcinoma cell line A431.

Tyrphostin AG 879 (AG 879) effectively inhibits HER2 ErbB2 with an IC50 of 1 μM, demonstrating 100- and 500-fold higher selectivity for ErbB2 over EGFR and PDGFR, respectively.